Ge Long Hui·2025-11-10 03:08Core Insights - Bank of America Securities reported that BeiGene's product revenue for Q3 reached $1.395 billion, representing a year-over-year growth of 40.4% [1] - Total revenue for the quarter was $1.412 billion, marking a year-over-year increase of 41%, primarily driven by a 51% year-over-year growth in Brukinsa [1] - The company achieved a net profit of $125 million for the period, reversing from a loss to profitability [1] - Management raised the full-year revenue guidance from $5 billion to $5.3 billion, now estimating between $5.1 billion and $5.3 billion [1] Financial Projections - Based on the performance in the first three quarters, the firm slightly adjusted its sales and expense forecasts [1] - Earnings per share forecasts for 2025 to 2027 were increased by 55.2%, 0.6%, and 0.4% respectively [1] - The target price for U.S. stocks was raised from $389 to $402.2, while the target price for H-shares increased from HKD 234.9 to HKD 242.87 [1] - The "Buy" rating was reiterated based on strong global commercial performance and stable progress in the R&D pipeline [1]